Possible scenario
Scientific Limits Surface
23% Chance
The initial result may prove real but narrower than the headline implies. Binding validation does not automatically translate into functional biology, therapeutic relevance, scalable manufacturing, or reliable generalization across protein families.
Secondary impacts
- Healthcare -0.2%
- Technology -0.1%
Tickers
- SDGR-0.5%
- DNA-0.4%
- RXRX-0.3%
Portfolio impact
S&P 500-0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.